Rasburicase Articles
ASH hears strong data on Novartis
22 December 2008
Sanofi's Elitek reduces PUA more than allopurinol
15 December 2008
53.7% US sales leap boosts Sanofi-Synthelabo
27 January 2003
Sanofi's Elitek approved in USA
22 July 2002
Tally of NCEs in 2001 lends credence to talk of R&D productivity
21 January 2002
Stock Commentary - Europe
14 June 2001
Stock Commentary - Europe
11 April 2001
Stock Commentary - Europe
5 April 2001
New Sanofi-Synthelabo cancer drug OKed in EU
30 March 2001
Showing 1-13 of 13 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
